Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin kappa variable 3-11 (IGKV3-11) is a **variable region gene segment** encoding part of the kappa light chain of immunoglobulins (antibodies) in humans[3][5]. The variable region (V) participates in forming the antigen recognition site of antibodies, contributing to their specificity and diversity through somatic recombination (V-(D)-J rearrangement) and somatic hypermutation[1]. IGKV3-11 serves as one of many variable gene segments recombined during B cell development, determining the antigen specificity of kappa light chain-containing antibodies[5][3]. While IGKV3-11 itself is not a druggable “target” like a receptor or enzyme, its sequence features and usage can be relevant in antibody engineering, diagnostics (such as minimal residual disease tracking in B cell lymphomas), and as a molecular fingerprint in immunopathology and immune repertoire studies[3][2]. Some studies investigate IGKV3 gene family members as potential immunogens or vaccine candidates in B cell malignancies, but IGKV3-11 specifically is not commonly targeted by drugs or therapeutics[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin kappa variable 3-11 (IGKV3-11).